ANIP - Insider Selling: Stephen P Carey Unloads $317K Of ANI Pharmaceuticals Stock | Benzinga
Stephen P Carey, SVP & CFO at ANI Pharmaceuticals (NASDAQ:ANIP), disclosed an insider sell on June 6, according to a recent SEC filing.
What Happened: Carey's recent move involves selling 5,000 shares of ANI Pharmaceuticals. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday. The total value is $317,900.
At Thursday morning, ANI Pharmaceuticals shares are down by 0.07%, trading at $66.95.
Get to Know ANI Pharmaceuticals Better
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
ANI Pharmaceuticals: A Financial Overview
Revenue Growth: ANI Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 28.7%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company ...